3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Epstein-Barr Virus Infections
2
Cytomegalovirus Infections
2
Colorectal Neoplasms
2
Adenoviridae Infections
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Cell Count
×
Clear all
NCT05887882
2026-04-24
PNOC028
University of California, San Francisco
Phase 1
Suspended
24 enrolled